NCT05128617 (PROTECT-06) is a clinical trial of Epirubicin-cyclophosphamide in Breast Cancer, sponsored by Institut de cancérologie Strasbourg Europe.

Who is sponsoring NCT05128617?

NCT05128617 is sponsored by Institut de cancérologie Strasbourg Europe.

What drugs are being tested in NCT05128617?

Interventions in NCT05128617: Epirubicin-cyclophosphamide, Paclitaxel.

What condition does NCT05128617 study?

NCT05128617 studies Breast Cancer.

Is NCT05128617 still recruiting?

NCT05128617 is currently completed. Last updated 8 June 2023.

Last reviewed 2023-06-08 · How we verify

NCT05128617: PROTECT-06

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study

Completed Last updated 8 June 2023

What this trial tests

trial testing Epirubicin-cyclophosphamide in Breast Cancer in 20 participants. Completed in 30 May 2023.

Timeline

4 November 2021

Primary endpoint
30 May 2023

30 May 2023

Quick facts

Lead sponsor	Institut de cancérologie Strasbourg Europe
Status	Completed
Study type	OBSERVATIONAL
Enrollment	20
Start date	4 November 2021
Primary completion	30 May 2023
Estimated completion	30 May 2023
Sites	1 location across France

Drugs / interventions tested

Epirubicin-cyclophosphamide
Paclitaxel — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Institut de cancérologie Strasbourg Europe — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chemotherapy treatments such as epirubicin-cyclophosphamid or paclitaxel lead to severe off-target side effects such as skeletal muscle deconditioning. To date, three different studies investigated skeletal muscle decontioning in breast cancer patients, through long term protocols including all chemotherapy cycle treatment, and highlighted both structural alterations and impaired cellular processes. However, no study is currently availbale on the acute effect of one single chemotherapy administration in breast cancer patients skeletal muscle tissue. Our study is therefore dedicated to the investigation of the acute effect of the first dose administration of both Epuribicin/cyclophosphamide and Paclitaxel chemotherapies on skeletal muscle of breast cancer patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A single chemotherapy administration induces muscle atrophy, mitochondrial alterations and apoptosis in breast cancer patients.
Mallard J, Hucteau E, Bender L, Moinard-Butot F, et al · · 2024 · cited 14× · PMID 38183352 · DOI 10.1002/jcsm.13414

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Institut de cancérologie Strasbourg Europe trials

Trials by the same sponsor.

NCT06476704 — Study of Preoperative RAdiation Therapy With Concomitant Liposomal Transcrocetin (L-TC) in Soft tISsue Sarcomas · Phase 2 · not yet recruiting
NCT06477939 — Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomi · Phase 3 · not yet recruiting
NCT06458517 — Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Muco · NA · not yet recruiting
NCT06775119 — Feasibility Study of a Neuromuscular Fatigue Test and Associated Hemodynamic Responses: Application in Healthy Volunteer · NA · completed
NCT06536556 — Effects of a Single Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: Comparison of Paclitaxel v · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05128617 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut de cancérologie Strasbourg Europe
Last refreshed: 8 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05128617.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing